Atomoxetine combined with DAW2022 for obstructive sleep apnea
Tests atomoxetine with DAW2022 to lower obstructive sleep apnea severity in adults.
Key facts
- Who runs it
- Brigham and Women's Hospital
- Where
- Boston, United StatesSee the site
- Trial code
- Registry title
- Atomoxetine and DAW2022 on OSA Severity
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 18 people, planned
- Started
- 1 Jun 2022
- Expected to end
- 1 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Placebo oral capsule
- Atomoxetine Oral Capsule [Strattera]
- Record updated
- 10 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with moderate to severe obstructive sleep apnea, where breathing stops again and again during sleep. It tests atomoxetine with DAW2020 against a placebo (dummy pill).
- Age
- 21 Years to 70 Years
- Sex
- All sexes can join
- Disease stage
- Moderate to severe obstructive sleep apnea (AHI ≥ 15 events/hr, meaning at least 15 breathing pauses or drops per hour of sleep)
- Earlier treatment
- People who use medicines that speed up or slow down breathing (such as opioids, barbiturates, acetazolamide, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid) cannot join. People who use SNRIs/SSRIs, or medicines that lengthen the QTc interval (a heart rhythm measure), cannot join.
Main reasons for not taking part
- Major organ disease, nerve or muscle disease, heart failure, or another unstable major illness
- Breathing problems during sleep, or lung problems, other than obstructive sleep apnea
- Other sleep disorders: periodic limb movements (arousal index > 10/hr), narcolepsy or parasomnias
- Allergy to the study drug (angioedema or urticaria), or reasons not to take DAW2020
- Low potassium, low magnesium, uncontrolled thyroid disease, or severe claustrophobia
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Moderate-to-severe OSA (AHI ≥ 15 events/hr)
Who cannot take part
- Use of medications expected to stimulate or depress respiration (including opioids, barbiturates, acetazolamide, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid)
- All participants will be healthy and without major organ system disease that would preclude undergoing the physiological measurements
- Conditions likely to affect OSA physiology: neuromuscular disease or other major neurological disorder, heart failure (also below), or any other unstable major medical condition
- Sleep disordered breathing or respiratory disorders other than obstructive sleep apnea:
- Other sleep disorders: periodic limb movements (periodic limb movement arousal index > 10/hr), narcolepsy, or parasomnias
- Hypersensitivity to the study drug (angioedema or urticaria)
- Hypokaliemia, hypomagnesemia, uncontrolled thyroid disease
- Use of medications that lengthen QTc interval
- Use of SNRIs/SSRIs
- Contraindications to DAW2020
- Severe claustrophobia
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 70 years old?
Where in United States
- Brigham and Women's HospitalBoston, United StatesContact: Nicole CalianeseTaking people
About the trial
What the trial wants to find out
Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. In previous research atomoxetine and oxybutynin showed promising effect at reducing OSA severity, however they reduced arousal threshold, one of the key traits responsible for OSA. Since oxybutynin was used mainly as a hypnotic, but it is burdened by several anti-cholinergic side effects, DAW2020, a hypnotic which prolonged the total sleep time in a previous trial in OSA patients, could be a better candidate to associate with atomoxetine.
The 2 groups in the trial
- Placebo oral capsulesPlacebo, for comparison
Placebo (2 pills) before sleep for a week
Treatment: Placebo oral capsule
- Atomoxetine and DAW2020 oral capsulesExisting treatment, for comparison
DAW2020 34 mg 4 h before sleep, single night administration for a week. Simultaneous administration of atomoxetine 40 mg for 3 days 30 min before sleep, 80 mg for the following 4 days, 30 min before sleep
Treatment: Atomoxetine Oral Capsule [Strattera]
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Atomoxetine and DAW2022 on OSA Severity
- Plain-language title
- Atomoxetine combined with DAW2022 for obstructive sleep apneaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT05350215, who can take part
- Publications
- Record updated
- 10 July 2026